38 related articles for article (PubMed ID: 22512403)
1. Pioglitazone in acromegaly - an open-label, prospective study.
Kim DD; Goh J; Panossian Z; Gamble G; Holdaway I; Grey A
Clin Endocrinol (Oxf); 2012 Oct; 77(4):575-8. PubMed ID: 22512403
[TBL] [Abstract][Full Text] [Related]
2. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
3. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
[TBL] [Abstract][Full Text] [Related]
4. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
5. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
6. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status.
Espinosa-de-Los-Monteros AL; Sosa E; Cheng S; Ochoa R; Sandoval C; Guinto G; Mendoza V; Hernández I; Molina M; Mercado M
Clin Endocrinol (Oxf); 2006 Mar; 64(3):245-9. PubMed ID: 16487431
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
8. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
9. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
10. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity.
Frajese GV; Taylor NF; Jenkins PJ; Besser GM; Monson JP
Horm Res; 2004; 61(5):246-51. PubMed ID: 15004437
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
[TBL] [Abstract][Full Text] [Related]
13. Excessively high soluble Klotho in patients with acromegaly.
Sze L; Bernays RL; Zwimpfer C; Wiesli P; Brändle M; Schmid C
J Intern Med; 2012 Jul; 272(1):93-7. PubMed ID: 22452701
[TBL] [Abstract][Full Text] [Related]
14. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
15. Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.
Bogazzi F; Rossi G; Lombardi M; Raggi F; Urbani C; Sardella C; Cosci C; Martino E
J Endocrinol Invest; 2011 Feb; 34(2):e43-51. PubMed ID: 20671417
[TBL] [Abstract][Full Text] [Related]
16. Biochemical monitoring of disease activity after surgery for acromegaly.
Shalet SM
J Clin Endocrinol Metab; 2004 Feb; 89(2):492-4. PubMed ID: 14764750
[No Abstract] [Full Text] [Related]
17. The comprehensive impact on human body induced by resolution of growth hormone excess.
Zhang Z; Li Q; He W; Qiu H; Ye H; Wang Y; Shen M; He M; Yu Y; Shou X; Huang C; Yu H; Huang G; Tang W; Geng D; Fu C; Liu C; Ma Z; Ye Z; Zhang Q; Zhang Y; Shen Y; Yang Y; Wang M; Liu X; Lu Y; Hu R; Mao Y; Zhou L; Li Y; Li S; Tritos NA; Zhao Y
Eur J Endocrinol; 2018 Apr; 178(4):365-375. PubMed ID: 29386229
[TBL] [Abstract][Full Text] [Related]
18. Editorial: acromegaly--consensus, what consensus?
Trainer PJ
J Clin Endocrinol Metab; 2002 Aug; 87(8):3534-6. PubMed ID: 12161470
[No Abstract] [Full Text] [Related]
19. Letter re: Monitoring the response to treatment in acromegaly.
Ayuk J; Sheppard MC; Bates AS; Stewart PM
J Clin Endocrinol Metab; 2005 Aug; 90(8):4980. PubMed ID: 16087964
[No Abstract] [Full Text] [Related]
20. Endocrinology: Diabetes and Acromegaly.
Shepardson HC
Cal West Med; 1927 Oct; 27(4):530-1. PubMed ID: 18740501
[No Abstract] [Full Text] [Related]
[Next] [New Search]
